Investigation of COVID-19 fear, treatment compliance, and metabolic control of patients with type 2 diabetes mellitus during the pandemic

Basit Öğe Kaydı
dc.contributor.authorMenekli, Tugba
dc.contributor.authorYaprak, Bulent
dc.contributor.authorTureyen, Aynur
dc.contributor.authorSenturk, Sibel
dc.date.accessioned2026-06-19T06:39:44Z
dc.date.available2026-06-19T06:39:44Z
dc.date.issued2022
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractAims: This study was carried out to investigate fear levels, treatment compliance, and metabolic control of type II Diabetes Mellitus patients during the COVID-19 pandemic.Methods: The study employed a single-center, observational design and was conducted between January and April 2021. The study consisted of 303 patients who attended the internal medicine outpatient clinic of a uni-versity hospital in Turkey. For data collection, the Patient Identification Form, COVID-19 Fear Scale, and the Type II Diabetes Treatment Compliance Scale were used. The study complied with the Helsinki Declaration criteria. IBM SPSS v25.0 statistics package program was used for data analysis.Results: The mean age of the patients was 45.8 +/- 7.5 years, the mean duration of illness was 8.2 +/- 3.6 years. Moreover, 40.6% of patients presented with poor levels of treatment compliance. In addition, the mean FCV-19S score of the patients was 29.1 +/- 3.05. It was noticeable that those with high mean scores of FCV-19S had poor compliance with treatment and metabolic control during the pandemic (p < 0.05). Practice implications: Fear of COVID-19 negatively affects treatment compliance and metabolic control of type II diabetes patients. The patients avoided attending their regular follow-ups at the hospital due to fear of con-tracting COVID-19. In order to reduce the fear of COVID-19 it is paramount to maintain optimum metabolic control and treatment compliance.
dc.identifier.doi10.1016/j.pcd.2022.08.005
dc.identifier.endpage663
dc.identifier.issn1751-9918
dc.identifier.issn1878-0210
dc.identifier.issue5
dc.identifier.pmid36030171
dc.identifier.scopus2-s2.0-85136610518
dc.identifier.scopusqualityQ2
dc.identifier.startpage658
dc.identifier.urihttps://doi.org/10.1016/j.pcd.2022.08.005
dc.identifier.urihttps://hdl.handle.net/20.500.12899/5759
dc.identifier.volume16
dc.identifier.wosWOS:000875619200008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofPrimary Care Diabetes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260612
dc.subjectFear Of Covid-19
dc.subjectType 2 Diabetes
dc.subjectTreatment Compliance
dc.subjectMetabolic Control
dc.titleInvestigation of COVID-19 fear, treatment compliance, and metabolic control of patients with type 2 diabetes mellitus during the pandemic
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu